{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:04:56Z","timestamp":1770897896559,"version":"3.50.1"},"reference-count":13,"publisher":"Societas Neurologica Japonica","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rinsho Shinkeigaku"],"published-print":{"date-parts":[[2013]]},"DOI":"10.5692\/clinicalneurol.53.513","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T23:32:15Z","timestamp":1374795135000},"page":"513-517","source":"Crossref","is-referenced-by-count":23,"title":["A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment"],"prefix":"10.5692","volume":"53","author":[{"given":"Shoko","family":"Izaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Narukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikoaki","family":"Fukaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3663","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.","DOI":"10.1001\/archneur.63.3.390"},{"key":"2"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489.","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Eichel R, Meiner Z, Abramsky O, et al. Acute disseminating encephalomyelitis in neuromyelitis optica: closing the floodgates. Arch Neurol 2008;65:267-271.","DOI":"10.1001\/archneurol.2007.59"},{"key":"6"},{"key":"7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18:113-115.","DOI":"10.1177\/1352458511431973"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Tanaka M, Tanaka K, Komori M. Interferon-beta (1b) treatment in neuromyelitis optica. Eur Neurol 2009;62:167-170.","DOI":"10.1159\/000227277"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-245.","DOI":"10.1001\/archneurol.2011.216"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Brinkman V. FTY720 (Fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009;158:1173-1182.","DOI":"10.1111\/j.1476-5381.2009.00451.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Chiba K, Kataoka H, Seki N, et al. Fingolimod (FTY720), the sphingosine 1-phosphate receptor modulator, as a new therapeutic drug in multiple sclerosis. Inflamm Regen 2011;31:167-174.","DOI":"10.2492\/inflammregen.31.167"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 2010;16:1443-1452.","DOI":"10.1177\/1352458510379247"}],"container-title":["Rinsho Shinkeigaku"],"original-title":["\u30d5\u30a3\u30f3\u30b4\u30ea\u30e2\u30c9\u6295\u4e0e10\u65e5\u5f8c\u306b\u591a\u5de3\u6027\u767d\u8cea\u75c5\u5909\u3092\u5448\u3057\u6025\u6027\u5897\u60aa\u3092\u793a\u3057\u305f\u8996\u795e\u7d4c\u810a\u9ac4\u708e\u95a2\u9023\u75be\u60a3\uff08NMOSD\uff09\u306e1\u4f8b"],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T20:06:40Z","timestamp":1621541200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/53\/7\/53_513\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.5692\/clinicalneurol.53.513","relation":{},"ISSN":["0009-918X","1882-0654"],"issn-type":[{"value":"0009-918X","type":"print"},{"value":"1882-0654","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}